Navigation Links
Human Pheromone Sciences Announces Third Quarter Results
Date:11/13/2008

Increase in revenue with reduction in loss for the quarter

SAN JOSE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the third quarter and nine months ended September 30, 2008. For the three month period ending September 30, 2008, net revenues of $262,000 represented a 10% increase from the revenues of $239,000 in the prior year period, and resulted in a net loss of $30,000 ($.01 per share) as compared with a net loss of $93,000 ($.02 per share) for the same period of 2007. For the nine month period ending September 30, 2008, net revenues of $764,000 were 15% lower than the previous year's $902,000, resulting in a net loss of $181,000 ($0.04 per share) as compared with a net loss of $54,000 ($0.01 per share) in the first nine months of 2007. At September 30, 2008, the Company reflected a cash balance of $1,082,000 compared with $1,437,000 at December 31, 2007, a $355,000 reduction for the nine months of the current year as compared to a decline of $390,000 during the nine months ending September 30, 2007. There was no bank indebtedness at either date.

A spokesperson indicated "the Company was pleased that its cash utilization was only $355,000 for the first nine months of the year, and that net current liquidity (cash, accounts receivable and inventory, less current liabilities excluding current portion of deferred revenue) decreased only $433,000 for the same nine month period. This lower than expected asset utilization was a result of revenues generated under new licensing agreements, and a concerted effort to only invest in programs that are designed to generate additional future revenues."

"However, we still recognize that the marketing plans of our licensees can create unpredicted volatility of our quarterly performance, and this is not an acceptable posture for the Company in the long-term. We will still continue to nurture
'/>"/>

SOURCE Human Pheromone Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transdermal Diclofenac enters Phase 1 Clinical Trial in Humans
2. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
4. Human Genome Sciences Announces Third Quarter 2008 Financial Results and Key Developments
5. Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
6. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
7. Complete Genomics Chooses Isilon IQ to Power Worlds First Complete Human Genome Sequencing Service
8. Human Genome Sciences to Sponsor Conference Call to Discuss Third Quarter 2008 Financial Results
9. Human Pheromone Sciences, Inc. - Shareholder Update
10. The human brain minimizes energy expenditure and integrates gravity in to the action plan
11. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... ChanTest, the leading expert in ion channels and ... development, and safety -- is one of eight organizations ... and Commercialization Program. Governor Ted Strickland and Interim Director ... the Ohio Third Frontier Commission, Mark Barbash, announced the ...
... Aegera Therapeutics is pleased to announce the initiation ... AEG33773, a novel, orally bio-available small molecule therapeutic ... , The Phase 2a study, entitled A Multicenter, ... Efficacy of AEG33773 versus Placebo in Patients with ...
... May 6 iZumi Bio, Inc., a biotechnology ... stem cell (iPS) technology with the mission of ... differentiation of patient cells, today announced the appointments ... (CTO) and Dushyant Pathak, Ph.D., as vice president ...
Cached Biology Technology:ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 3
(Date:4/17/2014)... and fragmentation of forests in the Amazon help ... contributing to rapid and widespread forest loss during ... The findings show that forests in the Amazon ... coupled with forest fires lead to large-scale loss ... Balch, assistant professor of geography, Penn State. , ...
(Date:4/17/2014)... Ind. -- Indiana University researchers have detected new early-warning ... diabetes. This discovery could have far-reaching implications for the ... care of over 25 million Americans. , "We had ... retinas at such early stages," said Ann Elsner, professor ... and lead author of the study. "We set out ...
(Date:4/17/2014)... Australian National University (ANU), have developed a new ... variability over the past 5.3 million years., The ... surrounding ice ages over the past two million ... carbon dioxide levels, global temperatures and sea levels., ... (UoS) and the National Oceanography Centre (NOC) in ...
Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Ancient sea-levels give new clues on ice ages 2
... in marine mammals, brains reveals that these animals are ... DDTs and PCBs, as well as emerging contaminants such ... lead author on the study currently in press and ... performed the research as a student in the Woods ...
... radio landscape has made it tough for Foghat to get ... to new research published in The American Naturalist . ... that the songs of white-crowned sparrows change over time in ... factors that drive the evolution of mating signals in birds. ...
... Institutes of Health is launching the first integrated, ... rare and neglected diseases. The $24 million program ... Rare and Neglected Diseases Program, or TRND. ... is unusual because TRND creates a drug development ...
Cached Biology News:Skip this cocktail party 2Skip this cocktail party 3Bird songs change with environment 2NIH announces new program to develop therapeutics for rare and neglected diseases 2NIH announces new program to develop therapeutics for rare and neglected diseases 3NIH announces new program to develop therapeutics for rare and neglected diseases 4NIH announces new program to develop therapeutics for rare and neglected diseases 5
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
Request Info...
Request Info...
Biology Products: